Covid: the five promising treatments administered or under study around the world – Sortaparis

Monoclonal antibodies, polyclonal, antivirals… The treatments against the Covid, currently under study or already administered, arouse the curiosity and questioning of researchers, in the hope of finding a remedy, preventive or not, to help eradicate the virus in the world.

A research which is scrutinized with a certain attention by the French and European health authorities, with a view to supplementing the vaccine arsenal and allowing people who cannot receive the vaccine to still protect themselves against the disease.

In total, five treatments are currently under the watchful eye of regulators:

Covid: molnupiravir, Merck’s promising treatment in phase 3 clinical trial
Good news in the fight against Covid! The Merck and Ridgeback Bio laboratories announced last April to have had promising results for a treatment against the virus, molnupiravir, which would significantly reduce the viral load of patients. An orally administered drug, the results of which from a phase 3 clinical trial are expected in September or October 2021. [Lire la suite]

Covid: Ronapreve, the preventive treatment authorized by the HAS for immunocompromised people
Immunosuppressed people, less protected against the coronavirus, will be authorized to receive preventive treatment against Covid-19, based on monoclonal antibodies, announced the High Authority for Health. [Lire la suite]

Covid: update on Xav-19, antibody treatment made in France undergoing clinical trial
What if, in the fight against Covid, we could count, in addition to the future vaccine, on antibody treatments? After Bamlanivimab, the treatment developed by the Eli Lilly laboratory, or even Regeneron, it is the turn of a French laboratory located in Nantes, Xenothera, to present its product undergoing clinical trial, Xav-19. A treatment which has just entered phase 3 of a clinical trial, for possible commercialization in the fall of 2021. [Lire la suite]

Covid – AstraZeneca: first promising results for preventive antibody treatment
The AstraZeneca laboratory unveiled on Friday August 20 the first promising results of a study on a preventive treatment of Covid by antibodies. A treatment that would reduce the risk of developing a severe form of the disease by 77%. We take stock! [Lire la suite]

Covid: RoActemra (Tocilizumab) as treatment under study by EMA
Tocilizumab, a treatment against Covid still under study? The European Medicines Agency has announced that it is testing hospitalized patients with RoActemra (Tocilizumab), an anti-inflammatory drug, in severe cases. A treatment capable of blocking the action of interleukin-6 and avoiding cytokine shocks, excess inflammation of the lungs. [Lire la suite]